| IVACAFTOR; IVACAFTOR, TEZACAFTOR | None | ||
| 150MG;150MG, 100MG, 75MG;75MG, 50MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| SYMDEKO is a combination of tezacaftor and ivacaftor, indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence. | |||
|
Yes
| |||
| SYMDEKO (COPACKAGED) | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 | Patent 20 | Patent 21 | Patent 22 | Patent 23 | Patent 24 | Patent 25 | Patent 26 | Patent 27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | |||||||||||||||||||||||||||
| ********** ** ***-******* ******** ************ | ****** *********** ** **** ********** | ********** ** ***-******* ******** ************ | ********** ** ***-******* ******** ************ | ********** ** ***-******* ******** ************ | ***** ***** ** *-[*,*-***(*,*-*************)-*-*************]-*,*-*******-*-************-*-*********** | ********** ** ***-******* ******** ************ | ********** ** ***-******* ******** ************ | ********** ** ***-******* ******** ************ | ***** ***** ** *-[*,*-***(*,*-*************)-*-*************]-*,*-*******-*-************-*-*********** | ************** ************ ** (*)-*-(*,*-*************[*][*,*]******-*-**)-*-(*-(*,*-***************)-*-******-*-(*-*******-*-************-*-**)-**-*****-*-**)*********************** *** ************** ******* | ***** ***** ** *-[*,*-***(*,*-*************)-*-*************]-*,*-*******-*-************-*-*********** | ***** ***** ** *[*,*-***(*,*-*************)-*-*************]-*,*-*******-*-************-*-*********** | ********** ** ***-******* ******** ************ | ********** ** ***-******* ******** ************ | ************** ************ ** (*)-*-(*,*-*************[*][*,*]******-*-**)-*-(*-(*,*-***************)-*-******-*-(*-*******-*-************-*-**)-**-*****-*-**) ******************-***** *** ************** ******* | ***** ***** ** (*)-*(*,*-*************[*][*,*]******-*-**)-*-(*-(*,*-***************)-*-******-*-(*-*******-*-************-*-**)-**-*****-*-**)*********************** | ************** ************ *** *** ********* ** ****** ******** ************* *********** ********* ******** ******** | ********** ** ***-******* ******** ************ | ************** *********** *** *************** ******* | ************** *********** *** *************** ******* | ***** ***** ** (*)-*(*,*-*************[*][*,*]******-*-**)-*-(*-(*,*-***************)-*-******-*-(*-*******-*-************-*-**)-**-*****-*-**)*********************** | ********** ** ***-******* ******** ************ | ************** ************ *** *** ********* ** ****** ******** ************* *********** ********* ******** ******** | ************** *********** *** *************** ******* | ****** *********** ** **** ********** | ********** ** ***-******* ******** ************ |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|